A day after announcing $880 Million
acquisition in the US, drug maker Lupin will acquire specialty product
portfolio from German company Temmler Pharma for an undisclosed amount. Temmler
business has a strong strategic fit with Lupin Hormosan business in Germany and
enables Lupin to bring an enhanced specialty CNS portfolio to German market.
Established in 1917, Temmler is a
part of Aenova Group, a pharmaceutical contract manufacturer. Hormosan, also a
German Pharma company was acquired by Lupin in 2008. Based in Marburg, Germany,
Temmler has a specialty portfolio of 13 products including key Central Nervous
System products and specialty products that address rare disease areas like
Myasthenia Gravis, Huntington disease as well as fast growing dermatology
products for anti-wart treatment.
This is Lupin sixth acquisition in
last 18 months. In February 2014, Lupin had acquired Netherland based Nanomi
for an undisclosed amount. A month later, it acquired control of Mexican company
Grin. In May this year, it bought Brazilian company Medquimica Industria
Farmaceutica.
Earlier this month, Lupin acquired
ZAO Bio Biocom in Russia, again for an undisclosed amount. On Thursday, it
announced acquisition of New Jersey based generic drugs firm Gavis for $880
Million. Gavis is the largest overseas acquisition by an Indian pharma company
in US.
No comments:
Post a Comment